aTyr Pharma Inc. (LIFE)
| Bid | n/a |
| Market Cap | 131.12M |
| Revenue (ttm) | 4.9M |
| Net Income (ttm) | -53.93M |
| EPS (ttm) | -0.88 |
| PE Ratio (ttm) | -2.159090909090909 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | n/a |
| Volume | 267,893 |
| Avg. Volume (20D) | 480,976 |
| Open | 1.86 |
| Previous Close | 1.85 |
| Day's Range | 1.82 - 1.95 |
| 52-Week Range | 1.08 - 2.45 |
| Beta | 1.19 |
About LIFE
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and ...
Analyst Forecast
According to 1 analyst ratings, the average rating for LIFE stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 1742.11% from the latest price.
Stock Forecasts
2 months ago · newsfilecorp.com
Trilogy AI Announces Closing of LIFE Financing, Concurrent Private PlacementsVancouver, British Columbia--(Newsfile Corp. - January 28, 2025) - Trilogy AI Corp. (CSE: TRAI) (OTCQB: TRAIF) (FSE: Y92) (formerly, Ambari Brands Inc.) (the "Company") is pleased to announce, furthe...
